As an expert in Biomedical Engineering and Clinical Validation Studies, I have analyzed the provided transcript from the "Moving Science Podcast: MS Innovation Challenge Special Edition." This discussion centers on leveraging quantitative oculomotor biomarkers for Multiple Sclerosis (MS) care.
Reviewing Group Recommendation
The ideal audience to review this material comprises the following specialized groups:
Clinical Neurologists and Neuro-Immunologists: Key stakeholders who manage MS patients and require validated tools for tracking Progression Independent of Relapse (PIRA) and subtle cognitive decline.
Ophthalmology/Optometry Specialists (Neuro-Optometrists): Those directly familiar with ocular motor function, visual stability, and the clinical translation of eye movement deficits.
Biomarker Development Scientists and Clinical Trial Designers: Experts focused on rigorous methodology, validation of novel endpoints, and establishing clinical utility for new diagnostic devices.
HealthTech Investors and Regulatory Specialists: Individuals concerned with the transition from academic technology (TSLO) to an FDA-cleared, reimbursed commercial product (CPT code/reimbursement strategy).
Artificial Intelligence/Machine Learning Engineers in Healthcare: Professionals tasked with developing robust, unbiased algorithms capable of extracting meaningful, validated patterns from high-dimensional oculomotor data.
Abstract
This podcast episode details the collaboration between C. Light Technologies (a startup founded by Dr. Christy Sheehy) and academic researchers (Dr. Jacqueline Theis and Dr. Ari Green) focused on developing a novel, quantitative oculomotor biomarker to detect Progression Independent of Relapse (PIRA) in Multiple Sclerosis (MS). The core innovation is the Retitra device, a tracking scanning laser ophthalmoscope (TSLO) developed by Dr. Sheehy during her PhD, which measures microscopic retinal eye movements.
The discussion establishes the critical unmet need: existing therapies manage relapses but fail to prevent insidious, progressive disability. Eye movements are proposed as a proxy for neurological function, tapping into cortical planning and attention networks linked to cognitive decline, which traditional metrics like the EDSS often miss. The methodology involves recording high-resolution retinal videos, tracking movement down to 30 microns (relative to cone photoreceptors/capillaries), providing objective quantification of deficits like drift, snapback, and square wave jerks. The team emphasizes the necessity of Big Data and AI/Machine Learning to process the complex datasets generated, ensuring clinical relevance and weeding out inherent human bias. The project, funded by the MS Innovation Challenge, aims to validate the TSLO's association and predictive power for PIRA and cognitive decline in early MS patients on aggressive therapy. Furthermore, the presenters highlight the device's progress toward regulatory clearance (already FDA-cleared as an Oculomotor Monitor) and securing a novel CPT reimbursement code for 2026, while also noting the technology's broader potential across various neurodegenerative and psychiatric conditions.
Exploring Retinal Oculomotor Biomarkers for MS Progression: C. Light Technologies' Innovation
0:06 Introduction to PIRA Challenge: The episode focuses on the MS Innovation Challenge-funded project aiming to quantify a novel oculomotor biomarker for PIRA (Progression Independent of Relapse), addressing the major unmet need in MS treatment: halting progressive disability despite effective relapse suppression.
1:25 Team Composition: The collaboration spans Optical Engineering (Dr. Sheehy, CEO/Co-founder), Clinical Neuro-Optometry (Dr. Theis, CMO), and Neurology/Biomarker Validation (Dr. Green, UCSF Professor).
4:20 PIRA Unmet Need: Current MS therapies primarily target immunological attacks (relapses); they are insufficient in preventing degeneration and worsening disability, necessitating more precise and sensitive progression measurement tools.
6:15 Eye Movements as Neurological Proxies: Ocular motor function relies on substantial brain networks (lobes, brain stem, cerebellum). Subtle nuances in eye movement (velocity, accuracy) offer an indirect, quantifiable biomarker of underlying neurologic function that standard MRI or clinical exams may miss.
8:08 Limitations of Standard Exams: Clinical exams detecting visible nystagmus or gross instability often occur too late to intervene effectively before significant patient morbidity (e.g., diplopia, functional impairment) sets in.
10:30 Founder Journey (Dr. Sheehy): The core technology, the Tracking Scanning Laser Ophthalmoscope (TSLO), evolved from a PhD project aiming for high-resolution retinal imaging without complex adaptive optics, prioritizing clinical viability (cheaper, compact).
13:15 Funding Trajectory: The journey involved developing prototypes at various international sites, securing non-dilutive NIH Small Business Grants (SBIR/STTR) to validate hypotheses regarding fixation changes in MS, culminating in venture backing in 2021.
15:46 Retitra Device Operation: The device is noninvasive, tabletop equipment requiring the patient to fixate on a target. It records 10-second monocular videos.
16:37 Cone Receptor Tracking: The technology tracks fixation by locking onto individual cone photoreceptors and capillary networks, providing tracking resolution down to $0.1$ degrees of visual angle ($\sim 30$ microns). This level detects subclinical jitter or shimmering not visible conventionally.
17:57 Objective Metrics: The output provides objective metrics (amplitude, speed) and pattern recognition (e.g., drift/snapback for nystagmus) previously only subjectively assessed in the clinic.
18:57 Big Data and AI Insight: Early data collection revealed massive data volumes. Dr. Sheehy exhibited vision in implementing Big Data analysis (what is now termed AI) early on (circa 2016-2017) to make the data clinically digestible.
21:25 AI Role in Validation: AI/Machine Learning is essential for recognizing subtle patterns across amplitude, speed, and multiple scans, helping to mitigate clinical biases and ensure the models are trained on valid data ("garbage in, garbage out").
23:22 MS Innovation Challenge Study: The funded study aims to use the highly sensitive TSLO in early MS patients (on high-efficacy therapy) to determine if the tool's measurements associate with and predict future PIRA development over several years.
26:34 Linking Eye Movements to Cognition: Fixational eye movements involve planning and attention maintenance, suggesting they are relevant biomarkers for tracking the slower, more insidious cognitive decline seen in MS, which is poorly monitored by EDSS scores.
30:13 Next Steps & Regulatory Status: The team is focused on establishing biomarker credibility and repeatability. Crucially, the device is already FDA-cleared as an Oculomotor Monitor and has secured a unique CPT reimbursement code launching in 2026, ensuring clinical availability alongside research utility.
34:55 Broader Application Vision: While MS was the strategic "beachhead" market due to existing therapeutics, the fundamental science of oculomotor changes applies to various neurodegenerative diseases (like Alzheimer's, given the founder's personal history) and psychiatric conditions, aiming for proactive brain health monitoring.